WuXi AppTec (OTCMKTS:WUXIF) is a global contract research, development and manufacturing organization serving the pharmaceutical, biotechnology and medical device industries. The company provides end-to-end solutions spanning discovery biology, medicinal chemistry, preclinical safety assessment, clinical trial support, and large-scale manufacturing of small molecules, biologics and advanced therapies. By integrating scientific expertise with state-of-the-art laboratory and production facilities, WuXi AppTec enables clients to accelerate the development of new treatments while managing time and cost pressures.
Key service offerings include custom synthesis and process research for active pharmaceutical ingredients (APIs), biologics development and manufacturing, cell line development, gene therapy support, as well as comprehensive analytical and testing services. The company’s preclinical services encompass in vitro and in vivo toxicology, pharmacology and bioanalytical testing, complementing its clinical trial manufacturing of drug substances and drug products under Good Manufacturing Practice (GMP) standards. In addition, WuXi AppTec’s genomics and molecular biology platforms support precision medicine and biomarker discovery initiatives.
Headquartered in Shanghai, China, WuXi AppTec operates a network of more than 100 facilities and laboratories across Asia, North America and Europe, including major sites in Wuxi, Suzhou, Shanghai, Philadelphia and St. Paul’s, Ireland. This global footprint allows the company to serve a diverse client base ranging from emerging biotech firms to large pharmaceutical corporations, facilitating seamless international collaboration and supply chain continuity.
Founded in 2000 by Dr. Ge Li, who continues to lead the company as chairman and chief executive officer, WuXi AppTec has grown through a combination of organic expansion and strategic acquisitions. The company’s leadership team, composed of seasoned industry veterans, emphasizes continuous innovation, quality compliance and customer-centric service delivery. WuXi AppTec is publicly traded on the Hong Kong and Shanghai stock exchanges and its American depositary shares trade on the OTC Markets under the ticker WUXIF.
